Document is current

Article History

Received: 7 April 2021

Revised: 5 June 2021

Accepted: 9 June 2021

First Online: 16 June 2021

Declarations

:

: Doriana Landi received travel funding from Biogen, Merck-Serono, Sanofi-Genzyme, Teva, speaking or consultations fees from Sanofi-Genzyme, Merck-Serono, Teva, Biogen, Roche. Alessio Signori has nothing to disclose. Maria Cellerino has nothing to disclose. Giuseppe Fenu received Speaking honoraria, Consultancies fees, Travel grants and Advisory board fees from Biogen Idec, Sanofi Genzyme, Merck Serono, and Novartis; member of the editorial board of BMC Neurology. Nicoletti Carolina Gabri received travel funding from Almirall, Biogen, Novartis and Sanofi-Genzyme, Merck-Serono. Marta Ponzano has nothing to disclose. Elisabetta Mancuso has nothing to disclose. Marzia Fronza has nothing to disclose. Maria Elena Ricchiuto has nothing to disclose. Giacomo Boffa has nothing to disclose. Matilde Inglese received grants NIH, NMSS, FISM; received fees for consultation from Roche, Genzyme, Merck, Biogen and Novartis. Marfia Girolama Alessandra received speaking or consultation fees from Almirall, Bayer-Schering, Biogen, Genzyme, Merck-Serono, Novartis, Teva, Sanofi-Genzyme. Eleonora Cocco received speaking or consultation fees from Almirall, Bayer, Biogen, Genzyme, Merck-Serono, Novartis, Teva, Sanofi, Roche. Jessica Frau serves on scientific advisory boards and received honoraria for speaking from Biogen, Merck, Genzyme, Almirall, Novartis, and Teva.

: The local ethics committee of the three centres involved approved the study protocol for retrospective analysis of the medical record-based MS data.

: All subjects signed an informed consent when they were initiated on treatment with FTY, allowing the anonymous use of their data for scientific purposes.

: All authors and contributors have agreed to publication.